EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments

Nevin A John iD, Bhavana S Solanky iD, Floriana De Angelis, Richard A Parker, Christopher J Weir, Jonathan Stutters, Ferran Prados Carrasco iD, Torben Schneider, Anisha Doshi, Alberto Calvi, Thomas Williams, Domenico Plantone und 7 weitere

Journal of Magnetic Resonance Imaging · 2024

DOI: 10.1002/jmri.29017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Magnetic Resonance Imaging, 2024. Verfasst von Nevin A John und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Neuroprotective Agents, Multiple Sclerosis, Chronic Progressive, Riluzole. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Efficacy and Mechanism Evaluation Programme (EME), University College London (UCL), Medical Research Council (MRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

1 H‐magnetic resonance spectroscopy ( 1 H‐MRS) may provide a direct index for the testing of medicines for neuroprotection and drug mechanisms in multiple sclerosis (MS) through measures of total N ‐acetyl‐aspartate (tNAA), total creatine (tCr), myo‐inositol (mIns), total‐choline (tCho), and glutamate + glutamine (Glx). Neurometabolites may be associated with clinical disability with evidence that baseline neuroaxonal integrity is associated with upper limb function and processing speed in secondary progressive MS (SPMS).

Purpose

To assess the effect on neurometabolites from three candidate drugs after 96‐weeks as seen by 1 H‐MRS and their association with clinical disability in SPMS. Study‐Type Longitudinal. Population 108 participants with SPMS randomized to receive neuroprotective drugs amiloride [mean age 55.4 (SD 7.4), 61% female], fluoxetine [55.6 (6.6), 71%], riluzole [54.6 (6.3), 68%], or placebo [54.8 (7.9), 67%]. Field Strength/Sequence 3‐Tesla. Chemical‐shift‐imaging 2D‐point‐resolved‐spectroscopy (PRESS), 3DT1. Assessment Brain metabolites in normal appearing white matter (NAWM) and gray matter (GM), brain volume, lesion load, nine‐hole peg test (9HPT), and paced auditory serial addition test were measured at baseline and at 96‐weeks. Statistical Tests Paired t ‐test was used to analyze metabolite changes in the placebo arm over 96‐weeks. Metabolite differences between treatment arms and placebo; and associations between baseline metabolites and upper limb function/information processing speed at 96‐weeks assessed using multiple linear regression models. P ‐value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroprotective AgentsMultiple Sclerosis, Chronic ProgressiveRiluzoleHumansFemaleMaleMiddle AgedLongitudinal StudiesAdultFluoxetineBrainInositolCreatineAspartic AcidCholineMagnetic Resonance SpectroscopyProton Magnetic Resonance SpectroscopyGlutamineGlutamic AcidMagnetic Resonance ImagingGray Matter

Stichwörter der Autor:innen

imaging biomarkermagnetic resonance spectroscopymultiple sclerosissecondary progressive multiple sclerosis

Substanzen

Neuroprotective AgentsRiluzoleFluoxetineInositolCreatineAspartic AcidCholineN-acetylaspartateGlutamineGlutamic Acid

Autor:innen und Institutionen

  • Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
  • Department of Neurology, Monash Health, Melbourne, Australia.
  • Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Centre for Medical Image Computing (CMIC), University College London, London, UK.
  • e-Health Center, Universitat Oberta de Catalunya, Barcelona, Spain.

ORCID-Profile: Nevin A John, Bhavana S Solanky, Ferran Prados Carrasco

Förderung

  • Efficacy and Mechanism Evaluation Programme (EME)
  • University College London (UCL)
  • Medical Research Council (MRC)
  • the UK Multiple Sclerosis Society
  • the National Multiple Sclerosis Society (USA NMSS)
  • National Institute for Health Research (NIHR)
  • University of Edinburgh
  • the National Institute for Health Research University College London Hospitals (NIHR-UCLH)

Zitieren

APA

John, N. A., Solanky, B. S., De Angelis, F., Parker, R. A., Weir, C. J., Stutters, J., Carrasco, F. P., Schneider, T., Doshi, A., Calvi, A., Williams, T., Plantone, D., Monteverdi, A., MacManus, D., Marshall, I., Barkhof, F., Gandini Wheeler-Kingshott, C. A. M., Chataway, J., & MS‐SMART Investigators (2024). Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29017

Vancouver

John NA, Solanky BS, De Angelis F, Parker RA, Weir CJ, Stutters J, et al. Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments. Journal of Magnetic Resonance Imaging. 2024. doi:10.1002/jmri.29017

BibTeX
@article{John2024,
  author = {John, Nevin A and Solanky, Bhavana S and De Angelis, Floriana and Parker, Richard A and Weir, Christopher J and Stutters, Jonathan and Carrasco, Ferran Prados and Schneider, Torben and Doshi, Anisha and Calvi, Alberto and Williams, Thomas and Plantone, Domenico and Monteverdi, Anita and MacManus, David and Marshall, Ian and Barkhof, Frederik and Gandini Wheeler-Kingshott, Claudia A M and Chataway, Jeremy and MS‐SMART Investigators, MS‐SMART Investigators},
  title = {Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments},
  journal = {Journal of Magnetic Resonance Imaging},
  year = {2024},
  doi = {10.1002/jmri.29017}
}
Kostenlos starten →